A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis
- Authors:
- Wen Lu
- Bingling Dai
- Weina Ma
- Yanmin Zhang
View Affiliations
Affiliations: School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
- Published online on: August 8, 2012 https://doi.org/10.3892/ol.2012.855
-
Pages:
1109-1113
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
In the present study, we investigated the antitumor activity of HMQ1611, a novel synthetic taspine derivative, in vivo and evaluated associated potential antiangiogenesis mechanisms. The proliferation of A549 cells was examined by WST-1 assay in vitro. Tube formation and lung tissue vessel models were used to observe the antiangiogenic activity of HMQ1611. In addition, vascular enodthelial growth factor (VEGF) secretion and KDR kinase activities were measured by ELISA and the HTRF®KinEASETM-TK assay. In vivo, the antitumor activity was assessed by implantation of A549 cells in athymic mice. The results showed that HMQ1611 inhibited A549 cell proliferation and VEGF secretion, while it significantly inhibited tube formation and tissue vascularization. Furthermore, HMQ1611 inhibited A549 xenograft tumor growth. In conclusion, the results of our study suggest that HMQ1611 has latent properties for the inhibition of angiogenesis which are involved in its antitumor activity.
View References
|
1.
|
J FolkmanAnti-angiogenesis: a new concept
for therapy of solid tumorsAnn
Surg175409416197210.1097/00000658-197203000-000145077799
|
|
2.
|
N FerraraVascular endothelial growth
factor as a target for anticancer
therapyOncologist9210200410.1634/theoncologist.9-suppl_1-2
|
|
3.
|
J FolkmanWhat is the evidence that tumors
are angiogenesis dependent?J Natl Cancer
Inst8246199010.1093/jnci/82.1.41688381
|
|
4.
|
H HirteNovel developments in angiogenesis
cancer therapyCurr Oncol165054200910.3747/co.v16i3.44419526086
|
|
5.
|
N FerraraHP GerberJ LeCouterThe biology of
VEGF and its receptorsNat
Med9669676200310.1038/nm0603-66912778165
|
|
6.
|
KJ KimB LiJ WinerM ArmaniniN GillettHS
PhillipsN FerraraInhibition of vascular endothelial growth
factor-induced angiogenesis suppresses tumor growth in
vivoNature362841844199310.1038/362841a07683111
|
|
7.
|
N FerraraVascular endothelial growth
factor: basic science and clinical progressEndocr
Rev25581611200410.1210/er.2003-002715294883
|
|
8.
|
H ImotoT OsakiS TagaA OhgamiY IchiyoshiK
YasumotoVascular endothelial growth factor expression in
non-small-cell lung cancer: prognostic significance in squamous
cell carcinomaJ Thorac Cardiovasc
Surg11510071014199810.1016/S0022-5223(98)70398-89605068
|
|
9.
|
DM ParkinGlobal cancer statistics in the
year 2000Lancet Oncol2533543200111905707
|
|
10.
|
DN CarneyLung cancer - time to move on
from chemotherapyN Engl J
Med346126128200210.1056/NEJM20020110346021111784881
|
|
11.
|
ME HalatschU SchmidtJ Behnke-MurschA
UnterbergCR WirtzEpidermal growth factor receptor inhibition for
the treatment of glioblastoma multiforme and other malignant brain
tumorsCancer Treat
Rev327489200610.1016/j.ctrv.2006.01.00316488082
|
|
12.
|
J HardingB BurtnessCetuximab: an epidermal
growth factor receptor chimeric human-murine monoclonal
antibodyDrugs Today
(Barc)41107127200510.1358/dot.2005.41.2.88266215821783
|
|
13.
|
J Glade BenderEM CooneyJJ KandelDJ
YamashiroVascular remodeling and clinical resistance to
antiangiogenic cancer therapyDrug Resist
Updat7289300200415533766
|
|
14.
|
P CarmelietAngiogenesis in life, disease
and medicineNature438932936200510.1038/nature0447816355210
|
|
15.
|
D RibattiNovel angiogenesis inhibitors:
addressing the issue of redundancy in the angiogenic signaling
pathwayCancer Treatment
Rev37344352201110.1016/j.ctrv.2011.02.00221435792
|
|
16.
|
AP JekunenKJA KairemoInhibition of
malignant angiogenesisCancer Treat
Rev23263266199710.1016/S0305-7372(97)90014-19377596
|
|
17.
|
Y ZhangL HeL MengW LuoTaspine isolated
from Radix et Rhizoma Leonticis inhibits proliferation and
migration of endothelial cells as well as chicken chorioallantoic
membrane neovascularisationVascul Pharmacol1481291372008
|
|
18.
|
YM ZhangLC HeHY WangInhibitory effect of
taspine on mouse S180 sarcoma and its mechanismZhongguo Zhong Yao
Za Zhi329539562007(In Chinese)
|
|
19.
|
Y ZhangL HeY ZhouTaspine isolated from
Radix et Rhizoma Leonticis inhibits growth of human
umbilical vein endothelial cell (HUVEC) by inducing its
apoptosisPhytomedicine151121192008
|
|
20.
|
R GrepinG PagesMolecular mechanisms of
resistance to tumor antiangiogenic strategiesJ
Oncol2010835680201010.1155/2010/83568020224655
|
|
21.
|
LM EllisEpidermal growth factor receptor
in tumor angiogenesisHematol Oncol Clin North
Am1810071021200410.1016/j.hoc.2004.06.00215474332
|
|
22.
|
RK JainMolecular regulation of vessel
maturationNat Med9685693200310.1038/nm0603-68512778167
|
|
23.
|
S RousseauF HouleJ LandryJ Huotp38 MAP
kinase activation by vascular endothelial growth factor mediates
actin reorganization and cell migration in human endothelial
cellsOncogene1521692177199710.1038/sj.onc.12013809393975
|
